The autophagy-related gene PEA15 is a potential prognostic biomarker for early-stage endometrial carcinoma

  • 0Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

|

|

Summary

This summary is machine-generated.

Autophagy-related gene PEA15 improves prognostic stratification for early-stage endometrial carcinoma. High PEA15 expression correlates with poorer survival, acting as an independent prognostic biomarker for personalized treatment strategies.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genetics

Background

  • The Cancer Genome Atlas (TCGA) molecular classification aids endometrial carcinoma risk stratification.
  • Microsatellite instability (MSI) and copy-number low (CN-L) subtypes show similar survival outcomes.
  • Need for refined prognostic markers in early-stage endometrial carcinoma.

Purpose Of The Study

  • Identify autophagy-related molecular signatures for precise TCGA-based prognostic stratification.
  • Evaluate PEA15 as an independent prognostic factor, particularly in MSI and CN-L subtypes.
  • Correlate PEA15 protein expression with patient survival in early-stage endometrial cancer.

Main Methods

  • Univariate and multivariate Cox regression analyses on TCGA cohort.
  • Kaplan-Meier survival analysis for candidate autophagy-related genes.
  • Immunohistochemical analysis of PEA15 expression in institutional cohort tissue microarrays.

Main Results

  • NRG3, PEA15, DNAJB1, BAK1, DRAM1, KLHL24, ATF6, CDKN2A, MBTPS2, and UVRAG associated with survival.
  • PEA15 identified as an independent prognostic factor via multivariate analysis.
  • Elevated PEA15 expression linked to poorer overall and disease-free survival; confirmed as independent prognostic factor for recurrence in stage I endometrioid adenocarcinoma.

Conclusions

  • Autophagy-related gene PEA15 serves as an independent prognostic biomarker in early-stage endometrial carcinoma.
  • PEA15 enhances risk stratification between MSI and CN-L subtypes.
  • Immunohistochemical detection of PEA15 offers clinical potential for molecular classification and personalized management.